BioSig Technologies, Inc. Selects Access Strategy Partners to Accelerate Commercial Sales
December 21 2021 - 9:00AM
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the
"Company"), a medical technology company commercializing an
innovative signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced that it appointed Access Strategy
Partners, Inc. to advise on the next phase of the commercial
roll-out.
Led by medical device sales experts, Boston-based Access
Strategy Partners brings to BioSig deep expertise in
commercialization, contract management, execution, and value
proposition optimization. The company’s Co-Founder and President,
Jim Walker, is a healthcare executive with more than 30 years of
experience in sales, marketing, sales operations, and national
accounts management in some of the leading companies in the medical
device sector, including Boston Scientific Corporation (BSC) and
Johnson & Johnson. His experience spans domestic and
international responsibilities, focusing on strategic market
development and key customer management. During his 18-year career
with Boston Scientific Corporation, Mr. Walker established the
organization as a recognized leader with Group Purchasing
Organizations. He created a world-class Corporate Sales
organization that represented the full BSC portfolio to supply
chain executives across every level of market aggregation,
including group purchasing organizations (GPOs), national and
regional integrated delivery networks (IDNs), and National and
Regional Purchasing Alliances. Mr. Walker was the company’s lead
strategic pricing advisor and gained the support of the executive
management team to invest in and develop an enterprise-wide
contract management system that provides global pricing
intelligence and profitability analysis capabilities.
“ASPI was founded to provide strategic relationship management
for emerging medical device companies,” said Jim Walker. “Our sales
conversations are all about delivering excellent clinical and
economic value. BioSig and its breakthrough PURE
EP(TM) product bring meaningful benefits to physicians and
patients that we are thrilled to introduce to healthcare
providers.”
Under the terms of the new collaboration, Access Strategy
Partners will advise BioSig on all aspects of commercial strategy,
including economic value modeling, hospital administration
engagement, and contracting.
“Jim and his highly accomplished team at Access Strategy
Partners brings us proven success strategies in accelerating
commercialization. Look closely at ASPI’s track record in helping
emerging medical device companies, and you will see what we saw –
strong revenue growth rates with sustainability. We look forward to
learning from some of the brightest minds in medical device sales
as we leverage the key insights from our initial commercial efforts
to bring our disruptive technology to the next level of hospitals
nationwide,” commented Kenneth L. Londoner, Chairman, and CEO of
BioSig Technologies, Inc.
The PURE EP(TM) is an FDA 510(k) cleared non-invasive class
II device that aims to drive procedural efficiency and efficacy in
cardiac electrophysiology. To date, over 70 physicians have
completed over 1750 patient cases with the PURE
EP(TM) System.
Clinical data acquired by the PURE EP(TM) System in a
multi-center study at Texas Cardiac Arrhythmia Institute at St.
David’s Medical Center, Mayo Clinic Jacksonville and Massachusetts
General Hospital was recently published in the Journal of
Cardiovascular Electrophysiology and is available electronically
with open access via the Wiley Online Library. Study results showed
93% consensus across the blinded reviewers with a 75% overall
improvement in intracardiac signal quality and confidence in
interpreting PURE EP(TM) signals over conventional
sources.
The Company recently appointed a former Abbott senior sales
leader Mr. Gray Fleming as its Chief Commercial Officer. BioSig is
in a targeted commercial launch of the PURE EP(TM) System in the
Northeast, Texas, and Florida and is in regular use in some of the
country’s leading centers of excellence, including the Mayo Clinic
in Rochester, MN, and St. David’s Medical Center in Austin, TX.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EP(TM) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording, and
storing electrocardiographic and intracardiac signals for patients
undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Green Farms Road
Westport, CT 06880, US
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jun 2024 to Jul 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jul 2023 to Jul 2024